MASSACHUSETTS: Moderna Inc today raised its full-year sales forecast for its Covid-19 vaccine by 2.7% to US$19 billion, as it seeks to ramp up manufacturing following production problems last year.
The company also said that it was planning to buy back US$3 billion in shares.
The vaccine maker expects higher sales in the second half of the year as it believes the coronavirus pandemic will enter an “endemic phase”.
Moderna had previously projected sales of US$18.5 billion from its vaccine, with an additional US$3.5 billion in options.
It now expects US$3 billion in options.